AP2006003559A0 - Heteroaryl fused pyridines, pyrazines and pyrimidines as CRF 1 receptor ligands - Google Patents

Heteroaryl fused pyridines, pyrazines and pyrimidines as CRF 1 receptor ligands

Info

Publication number
AP2006003559A0
AP2006003559A0 AP2006003559A AP2006003559A AP2006003559A0 AP 2006003559 A0 AP2006003559 A0 AP 2006003559A0 AP 2006003559 A AP2006003559 A AP 2006003559A AP 2006003559 A AP2006003559 A AP 2006003559A AP 2006003559 A0 AP2006003559 A0 AP 2006003559A0
Authority
AP
ARIPO
Prior art keywords
pyrazines
crf
pyrimidines
receptor ligands
heteroaryl fused
Prior art date
Application number
AP2006003559A
Other languages
English (en)
Inventor
Ping Ge
Raymond F Horvath
Lu-Yan Zhang
Original Assignee
Neurogen Corp Ventis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34272952&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AP2006003559(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Neurogen Corp Ventis Pharmaceuticals Inc filed Critical Neurogen Corp Ventis Pharmaceuticals Inc
Publication of AP2006003559A0 publication Critical patent/AP2006003559A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AP2006003559A 2003-09-05 2004-09-03 Heteroaryl fused pyridines, pyrazines and pyrimidines as CRF 1 receptor ligands AP2006003559A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50041403P 2003-09-05 2003-09-05
PCT/US2004/028899 WO2005023806A2 (fr) 2003-09-05 2004-09-03 Pyridines, pyrazines et pyrimidines fusionnees avec heteroaryle utilisees comme ligands de recepteurs crf1

Publications (1)

Publication Number Publication Date
AP2006003559A0 true AP2006003559A0 (en) 2006-04-30

Family

ID=34272952

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2006003559A AP2006003559A0 (en) 2003-09-05 2004-09-03 Heteroaryl fused pyridines, pyrazines and pyrimidines as CRF 1 receptor ligands

Country Status (19)

Country Link
US (2) US20050113379A1 (fr)
EP (1) EP1680424A2 (fr)
JP (1) JP2007504271A (fr)
KR (1) KR20060088534A (fr)
CN (1) CN1878773A (fr)
AP (1) AP2006003559A0 (fr)
AR (1) AR045582A1 (fr)
AU (1) AU2004270713A1 (fr)
BR (1) BRPI0414087A (fr)
CA (1) CA2537829A1 (fr)
CR (1) CR8274A (fr)
EA (1) EA200600372A1 (fr)
EC (1) ECSP066408A (fr)
IL (1) IL174084A0 (fr)
MA (1) MA28086A1 (fr)
NO (1) NO20061180L (fr)
TW (1) TW200530232A (fr)
WO (1) WO2005023806A2 (fr)
ZA (1) ZA200601978B (fr)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005028480A2 (fr) * 2003-09-03 2005-03-31 Neurogen Corporation 5-aryl-pyrazolo[4,3-d]pyrimidines, pyridines, et pyrazines et composes associes
US8273750B2 (en) 2005-06-06 2012-09-25 Takeda Pharmaceutical Company Limited Organic compounds
RU2008110941A (ru) * 2005-08-25 2009-09-27 Ф.Хоффманн-Ля Рош Аг (Ch) ИНГИБИТОРЫ КИНАЗЫ p38 МАР И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
US8143285B2 (en) 2005-09-06 2012-03-27 Shionogi & Co., Ltd. Indolecarboxylic acid derivative having PGD2 receptor antagonistic activity
US7405302B2 (en) * 2005-10-11 2008-07-29 Amira Pharmaceuticals, Inc. 5-lipoxygenase-activating protein (FLAP) inhibitors
US7977359B2 (en) 2005-11-04 2011-07-12 Amira Pharmaceuticals, Inc. 5-lipdxygenase-activating protein (FLAP) inhibitors
GB2431927B (en) 2005-11-04 2010-03-17 Amira Pharmaceuticals Inc 5-Lipoxygenase-activating protein (FLAP) inhibitors
CN102775396B (zh) 2005-11-08 2014-10-08 沃泰克斯药物股份有限公司 Atp-结合弹夹转运蛋白的杂环调控剂
GB0525068D0 (en) 2005-12-08 2006-01-18 Novartis Ag Organic compounds
EP1961754A4 (fr) 2005-12-15 2009-11-11 Ono Pharmaceutical Co Compose heterocyclique bicyclique
TW200812588A (en) * 2006-05-15 2008-03-16 Neurogen Corp CRF1 receptor ligands comprising heteroaryl fused bicycles
TWI398252B (zh) 2006-05-26 2013-06-11 諾華公司 吡咯并嘧啶化合物及其用途
US9006258B2 (en) 2006-12-05 2015-04-14 Intra-Cellular Therapies, Inc. Method of treating female sexual dysfunction with a PDE1 inhibitor
WO2008076446A1 (fr) * 2006-12-18 2008-06-26 Coleman Peter R Procédé de détoxification accéléré de la dépendance aux opioïdes
JP2010513370A (ja) * 2006-12-19 2010-04-30 エフ．ホフマン−ラ ロシュ アーゲー ピラゾロ［３，４−ｄ］ピリミジンｐ３８ＭＡＰキナーゼインヒビター
WO2008083070A1 (fr) * 2006-12-29 2008-07-10 Neurogen Corporation Ligands des récepteurs du crf1 comprenant des groupes fonctionnels hétéroaryle bicycliques
CN104447716A (zh) 2007-05-09 2015-03-25 沃泰克斯药物股份有限公司 Cftr调节剂
ES2588238T3 (es) * 2007-12-06 2016-10-31 Intra-Cellular Therapies, Inc. Derivados de pirazolopirimidin-4,6-diona y su uso como producto farmacéutico
MX365732B (es) 2007-12-07 2019-06-12 Vertex Pharma Procesos para producir acidos cicloalquilcarboxamido-piridin benzoicos.
EP3683218B1 (fr) 2007-12-07 2024-09-18 Vertex Pharmaceuticals Incorporated Formes solides d'acide benzoïque 3-(6- (1- (2,2-difluorobenzo [d] [1,3] dioxol-5-yl) cyclopropanecarboxamido) -3-methylpyridin-2-yl)
NZ720282A (en) 2008-02-28 2017-12-22 Vertex Pharma Heteroaryl derivatives as cftr modulators
ES2522346T3 (es) 2008-08-22 2014-11-14 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de CDK
MX2011005936A (es) * 2008-12-06 2011-12-16 Intra Cellular Therapies Inc Compuestos organicos.
AU2009322904A1 (en) 2008-12-06 2010-06-10 Intra-Cellular Therapies, Inc. Organic compounds
JP5989993B2 (ja) 2008-12-06 2016-09-07 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 有機化合物
KR20110098732A (ko) 2008-12-06 2011-09-01 인트라-셀룰라 써래피스, 인코퍼레이티드. 유기 화합물
WO2010065147A1 (fr) 2008-12-06 2010-06-10 Intra-Cellular Therapies, Inc. Composés organiques
CN102231953A (zh) 2008-12-06 2011-11-02 细胞内治疗公司 有机化合物
US8349852B2 (en) 2009-01-13 2013-01-08 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
US8551996B2 (en) * 2009-02-20 2013-10-08 Emory University Compounds, compositions, methods of synthesis, and methods of treatment
US9468637B2 (en) 2009-05-13 2016-10-18 Intra-Cellular Therapies, Inc. Organic compounds
WO2011092290A1 (fr) 2010-02-01 2011-08-04 Novartis Ag Dérivés de pyrazolo[5,1-b] utilisés en tant qu'antagonistes du récepteur de crf-1
AR080056A1 (es) 2010-02-01 2012-03-07 Novartis Ag Derivados de ciclohexil-amida como antagonistas de los receptores de crf
EP2531490B1 (fr) 2010-02-02 2014-10-15 Novartis AG Dérivés de cyclohexylamide à titre d'antagonistes du récepteur crf
UY33227A (es) 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
JP2013523833A (ja) 2010-04-07 2013-06-17 バーテックス ファーマシューティカルズ インコーポレイテッド ３−（６−（１−（２，２−ジフルオロベンゾ［ｄ］［１，３］ジオキソール−５−イル）シクロプロパンカルボキサミド）−３−メチルピリジン−２−イル）安息香酸の医薬組成物およびその投与
WO2011153135A1 (fr) 2010-05-31 2011-12-08 Intra-Cellular Therapies, Inc. Composés organiques
US9434730B2 (en) 2010-05-31 2016-09-06 Intra-Cellular Therapies, Inc. PDE1 inhibitor compounds
US9763948B2 (en) 2010-05-31 2017-09-19 Intra-Cellular Therapies, Inc. PDE1 inhibitory compounds and methods
TW201206937A (en) 2010-05-31 2012-02-16 Intra Cellular Therapies Inc Organic compounds
RU2013120966A (ru) 2010-10-08 2014-11-20 Эббви Инк. ФУРО[3,2-d]ПИРИМИДИНОВЫЕ СОЕДИНЕНИЯ
AR086554A1 (es) 2011-05-27 2014-01-08 Novartis Ag Derivados de la piperidina 3-espirociclica como agonistas de receptores de la ghrelina
EP2717877B1 (fr) 2011-06-10 2017-11-08 Intra-Cellular Therapies, Inc. Composés organiques
NZ727015A (en) 2012-01-25 2017-12-22 Vertex Pharma Formulations of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
ES2644781T3 (es) * 2012-03-06 2017-11-30 Bayer Intellectual Property Gmbh Azabiciclos sustituidos y su uso
JP2015525202A (ja) 2012-05-03 2015-09-03 ノバルティス アーゲー グレリン受容体アゴニストとしての２，７−ジアザ−スピロ［４，５］デカ−７−イル誘導体のｌ−リンゴ酸塩およびその結晶形態
US9801882B2 (en) 2013-02-17 2017-10-31 Intra-Cellular Therapies, Inc. Phosphodiesterase-1 inhibitors and their use in treatment of cardiovascular diseases
US9545406B2 (en) 2013-03-15 2017-01-17 Intra-Cellular Therapies, Inc. Method of treating a CNS injury with a PDE1 inhibitor
CA2906640C (fr) 2013-03-15 2021-07-20 Intra-Cellular Therapies, Inc. Composes imidazo-[1,2-a] pyrazolo[4,3-e]pyrimidin-4[5h]-one substitues et compositions pharmaceutiques et leur utilisation en tant qu'inhibiteurs de la pde-1
KR102529049B1 (ko) 2013-08-14 2023-05-08 노파르티스 아게 암의 치료를 위한 조합 요법
AU2014349010C1 (en) 2013-11-12 2020-08-06 Vertex Pharmaceuticals Incorporated Process of preparing pharmaceutical compositions for the treatment of CFTR mediated diseases
EP3102576B8 (fr) 2014-02-03 2019-06-19 Vitae Pharmaceuticals, LLC Inhibiteurs de ror-gamma à base de dihydropyrrolopyridine
EP2940022B1 (fr) * 2014-04-30 2020-09-02 Masarykova Univerzita Furopyridines comme inhibiteurs de protèines kinases
WO2015196186A1 (fr) 2014-06-20 2015-12-23 Intra-Cellular Therapies, Inc. Composés organiques
WO2016022893A1 (fr) 2014-08-07 2016-02-11 Intra-Cellular Therapies, Inc. Composés organiques
US10285992B2 (en) 2014-08-07 2019-05-14 Intra-Cellular Therapies, Inc. Combinations of PDE1 inhibitors and NEP inhibitors and associated methods
BR112017005533B1 (pt) 2014-09-17 2023-10-10 Intra-Cellular Therapies, Inc Compostos inibidores de fosfodiesterase 1 (pde1), composição farmacêutica que compreende os ditos compostos e usos dos mesmos no tratamento de uma doença, distúrbio, e/ou lesão do snc e no tratamento e/ou na profilaxia de uma doença, distúrbio e/ou lesão do snp
PT3207043T (pt) 2014-10-14 2019-03-25 Vitae Pharmaceuticals Llc Inibidores de di-hidropirrolopiridina de ror-gama
US9845308B2 (en) 2014-11-05 2017-12-19 Vitae Pharmaceuticals, Inc. Isoindoline inhibitors of ROR-gamma
US9663515B2 (en) 2014-11-05 2017-05-30 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ROR-gamma
RU2691136C2 (ru) 2014-11-18 2019-06-11 Вертекс Фармасьютикалз Инкорпорейтед Способ проведения высокопроизводительной тестовой высокоэффективной жидкостной хроматографии
TW201625635A (zh) 2014-11-21 2016-07-16 默沙東藥廠 作為可溶性鳥苷酸環化酶活化劑之三唑并吡基衍生物
WO2017024018A1 (fr) 2015-08-05 2017-02-09 Vitae Pharmaceuticals, Inc. Modulateurs de ror-gamma
US11008340B2 (en) 2015-11-20 2021-05-18 Vitae Pharmaceuticals, Llc Modulators of ROR-gamma
TW202220968A (zh) 2016-01-29 2022-06-01 美商維它藥物有限責任公司 ＲＯＲ－γ調節劑
EP3436083A4 (fr) 2016-03-28 2019-11-27 Intra-Cellular Therapies, Inc. Nouvelles compositions et méthodes
US9481674B1 (en) 2016-06-10 2016-11-01 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ROR-gamma
EP3510029B1 (fr) * 2016-09-07 2025-11-05 The Regents of The University of California Antagonistes allostériques du récepteur 1 du facteur de libération de la corticotropine (crfr1) qui diminuent la p-tau et améliorent la cognition
WO2018049417A1 (fr) 2016-09-12 2018-03-15 Intra-Cellular Therapies, Inc. Nouvelles utilisations
JP2020528904A (ja) 2017-07-24 2020-10-01 ヴァイティー ファーマシューティカルズ，エルエルシー ＲＯＲγの阻害剤
WO2019018975A1 (fr) 2017-07-24 2019-01-31 Vitae Pharmaceuticals, Inc. Inhibiteurs de ror gamma
JP7401442B2 (ja) 2018-01-31 2023-12-19 イントラ－セルラー・セラピーズ・インコーポレイテッド 新規使用
CN110437846B (zh) * 2019-08-30 2022-02-25 陕西师范大学 含炔键的氟取代苯并噁唑液晶化合物及其制备方法
EP4025202A4 (fr) 2019-09-03 2023-08-02 Intra-Cellular Therapies, Inc. Nouveaux composés
KR20220140515A (ko) 2020-01-13 2022-10-18 버지 애널리틱스, 인크. 치환된 피라졸로-피리미딘 및 그의 용도
US12364695B2 (en) 2020-06-02 2025-07-22 Intra-Cellular Therapies, Inc. Methods of treating inflammatory disease

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2153494C2 (ru) * 1993-10-12 2000-07-27 Дзе Дюпон Мерк Фармасьютикал Компани 1-n-алкил-n-арилпиримидинамины, способ лечения заболеваний, фармацевтическая композиция
US6020492A (en) * 1995-05-12 2000-02-01 Neurogen Corporation Deazapurine derivatives; a new class of CRF1 specific ligands
JP3964478B2 (ja) * 1995-06-30 2007-08-22 エーザイ・アール・アンド・ディー・マネジメント株式会社 ヘテロ環含有カルボン酸誘導体及びそれを含有する医薬
IL127566A0 (en) * 1996-08-28 1999-10-28 Pfizer Substituted 6,5-hetero- bicyclic derivatives
JP2002510687A (ja) * 1998-04-02 2002-04-09 ニューロゲン コーポレイション アミノアルキル置換ピロロ［２，３−ｂ］ピリジンおよびピロロ［２，３−ｄ］ピリミジン誘導体：ｃｒｆ１レセプタのモジュレータ
WO2002000623A2 (fr) * 2000-06-26 2002-01-03 Neurogen Corporation 4-oxy-pyridines substituees a fusion aryle
DE10229777A1 (de) * 2002-07-03 2004-01-29 Bayer Ag Indolin-Phenylsulfonamid-Derivate
EP1620095A4 (fr) * 2003-04-24 2009-04-01 Merck & Co Inc Inhibiteurs de l'activite akt

Also Published As

Publication number Publication date
KR20060088534A (ko) 2006-08-04
JP2007504271A (ja) 2007-03-01
AR045582A1 (es) 2005-11-02
CR8274A (es) 2008-06-10
EP1680424A2 (fr) 2006-07-19
TW200530232A (en) 2005-09-16
ZA200601978B (en) 2007-05-30
MA28086A1 (fr) 2006-08-01
AU2004270713A1 (en) 2005-03-17
WO2005023806A3 (fr) 2005-06-02
CA2537829A1 (fr) 2005-03-17
US20060199823A1 (en) 2006-09-07
NO20061180L (no) 2006-03-31
US20050113379A1 (en) 2005-05-26
ECSP066408A (es) 2006-09-18
WO2005023806A2 (fr) 2005-03-17
BRPI0414087A (pt) 2006-10-31
IL174084A0 (en) 2008-02-09
EA200600372A1 (ru) 2006-08-25
CN1878773A (zh) 2006-12-13

Similar Documents

Publication Publication Date Title
AP2006003559A0 (en) Heteroaryl fused pyridines, pyrazines and pyrimidines as CRF 1 receptor ligands
IL158669A0 (en) Substituted pyrazinones, pyridines and pyrimidines as corticotropin releasing factor ligands
AU4562001A (en) Aryl substituted pyridines, pyrimidines, pyrazines and triazines and the use thereof
PL375390A1 (en) 4-trifluoromethylpyrazolyl substituted pyridines and pyrimidines
HUP0400249A3 (en) Pyridine derivatives as 5-ht receptor ligands and uses thereof
IL176805A0 (en) Novel pyridine derivative and pyrimidine derivative (1)
IL231992A0 (en) Heteroaryl-modified pyrrolo[2,3-b]pyridines and pyrrolo[3,2-b]pyrimidines as Janus kinase inhibitors
PT1381363E (pt) Derivados de imidazo-(1,2-a)-piridina como antagonistas mglur5
AU2002348503A1 (en) Quinuclidine-substituted heteroaromatic compounds as ligands at nicotinic acetylcholine receptors
PL370480A1 (en) Aminopyrimidines and pyridines
ZA200705040B (en) 2,4 (4,6) pyrimidine derivatives
DE50305279D1 (de) 4-trifluormethylpyrazolyl substituierte pyridine und pyrimidine
IL163287A (en) HETEROARYL SUBSTITUTED 2 - PYRIDINYL AND 2 - PYRIMIDINYL - 6,7,8,9 - TETRAHYDROPYRIMIDO [1,2-a] PYRIMIDIN - 4 - ONE DERIVATIVES
MXPA03004136A (es) Derivados de pirimidina y su uso como ligandos del receptor de neuropeptido y (npy).
IL169318A0 (en) Pyrimidines, methods for the production thereof, and use thereof
HK1093504A (en) Heteroaryl fused pyridines, pyrazines and pyrimidines as crf1 receptor ligands
PL367615A1 (en) 6-(2,6-difluorophenyl)-triazolopyrimidines as fungicides
PL1641797T3 (pl) Wodoromesylan 4-(4-trans-hydroksycykloheksylo)amino-2-fenylo-7H-pirolo[2,3d]pirymidyny oraz jego różne postacie polimorficzne
DE50106542D1 (de) Substituierte 3,4-dihydro-pyrido[1,2-a]pyrimidine
GB0304901D0 (en) Novel aminopyridine derivatives as mGIuR5 antagonists
AU2003265175A8 (en) Pyridazinone and pyridone derivatives as adenosine antagonists
HK1089938A (en) 2-aminoethyl substituted pyrimidin-2-ones, cyclopropanes, pyrazolines, pyrimidines and benzothiazepines and their use as urotensin ii and somatostatins 5 receptor ligands
HK1096666A (en) Nicotinic acetylcholine receptor ligands